← Leaderboards
Carolyn Wasserheit
New York University School Of Medicine
$42,012
Attributed
$42,012
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$42,012 · 2
By mechanism
M01$42,012 · 2
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Howard S Hochster$9,390,994
- Fred Valentine$14,208,248
- Franco M Muggia$5,360,861
- William Borkowsky$9,487,417
- Jay Cooper$168,048
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationNeoplasm /Cancer ChemotherapyClinical Trial Phase IDrug Screening /EvaluationPharmacokineticsClinical ResearchHuman SubjectPaclitaxelRetinoateBreast NeoplasmsTamoxifenCombination Cancer TherapyCombination ChemotherapyDosageDoxorubicinFemaleNeoplasm /Cancer Relapse /Recurrence
Grant awards (8)
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER$0
M01 · FY2002 · RR
DOXIL &TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2002 · RR
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER$0
M01 · FY2001 · RR
DOXIL &TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2001 · RR
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER$21,006
M01 · FY2000 · RR
DOXIL &TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES$21,006
M01 · FY2000 · RR
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER$0
M01 · FY2000 · RR
DOXIL &TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR